11068 A 0 0.1 trials
11068 A 1 0.1 show
11068 A 2 0.1 avastin
11068 A 3 0.1 ,
11068 A 4 0.1 which
11068 A 5 0.1 is
11068 A 6 0.1 used
11068 A 7 0.1 in
11068 A 8 0.1 several
11068 A 9 0.1 other
11068 A 10 0.1 cancers
11068 A 11 0.1 ,
11068 A 12 0.1 gives
11068 A 13 0.1 women
11068 A 14 0.1 around
11068 A 15 0.1 four
11068 A 16 0.1 months
11068 A 17 0.1 extra
11068 A 18 0.1 life
11068 A 19 0.1 .
11068 A 20 0.1 the
11068 A 21 0.1 drug
11068 A 22 0.1 plus
11068 A 23 0.1 chemotherapy
11068 A 24 0.1 has
11068 A 25 0.1 now
11068 A 26 0.1 been
11068 A 27 0.1 licensed
11068 A 28 0.1 by
11068 A 29 0.1 european
11068 A 30 0.1 regulators
11068 A 31 0.1 .
11068 A 32 0.1 patients
11068 A 33 0.1 will
11068 A 34 0.1 have
11068 A 35 0.1 access
11068 A 36 0.1 via
11068 A 37 0.1 the
11068 A 38 0.1 cancer
11068 A 39 0.1 drugs
11068 A 40 0.1 fund
11068 A 41 0.1 cdf
11068 A 42 0.1 until
11068 A 43 0.1 it
11068 A 44 0.1 is
11068 A 45 0.1 considered
11068 A 46 0.1 for
11068 A 47 0.1 routine
11068 A 48 0.1 nhs
11068 A 49 0.1 use
11068 A 50 0.1 .
11068 A 51 0.1 it
11068 A 52 0.1 has
11068 A 53 0.1 been
11068 A 54 0.1 available
11068 A 55 0.1 in
11068 A 56 0.1 england
11068 A 57 0.1 via
11068 A 58 0.1 the
11068 A 59 0.1 cdf
11068 A 60 0.1 since
11068 A 61 0.1 last
11068 A 62 0.1 march
11068 A 63 0.1 pending
11068 A 64 0.1 licensing
11068 A 65 0.1 .
11068 A 66 0.1 each
11068 A 67 0.1 year
11068 A 68 0.1 an
11068 A 69 0.1 estimated
11068 A 70 0.1 600
11068 A 71 0.1 women
11068 A 72 0.1 with
11068 A 73 0.1 advanced
11068 A 74 0.1 cervical
11068 A 75 0.1 cancer
11068 A 76 0.1 could
11068 A 77 0.1 benefit
11068 A 78 0.1 from
11068 A 79 0.1 avastin
11068 A 80 0.1 ,
11068 A 81 0.1 costing
11068 A 82 0.1 3,370
11068 A 83 0.1 for
11068 A 84 0.1 a
11068 A 85 0.1 month's
11068 A 86 0.1 treatment
11068 A 87 0.1 .
